Being diagnosed with non-Hodgkin lymphoma can quickly lead to a confusing list of treatment names—chemotherapy, rituximab, targeted therapy, CAR T-cell therapy, radiation, stem cell transplant, and sometimes even “watch and wait.” So which treatment do you actually need?
*AI-generated image - for illustration only. Clinical accuracy is not guaranteed.
Non-Hodgkin lymphoma treatment depends mainly on the exact lymphoma subtype, how quickly it is growing, its stage, symptoms, biological markers, previous treatment, and your overall health.
This is important because non-Hodgkin lymphoma, or NHL, is not one disease. It includes many different B-cell and T-cell lymphomas, and their treatment can be very different.
For a broader overview of the disease, see our main guide to lymphoma treatment.
First, What Type of Non-Hodgkin Lymphoma Do You Have?
Before discussing treatment options, doctors need an accurate biopsy diagnosis. Non-Hodgkin lymphomas are broadly classified according to the lymphocyte in which they develop:
- B-cell lymphomas – the majority of NHL cases
- T-cell and NK-cell lymphomas – less common and often treated differently
They are also often described according to their behaviour:
| Indolent Lymphoma | Aggressive Lymphoma |
|---|---|
| Usually grows slowly | Can grow rapidly |
| May cause few symptoms initially | Often requires prompt treatment |
| Some patients can initially be monitored | Treatment is generally started after diagnosis and staging |
| Often managed over many years | Some types can be treated with curative intent |
| Example: many follicular lymphomas | Example: diffuse large B-cell lymphoma |
Slow-growing does not automatically mean harmless, and aggressive does not mean untreatable. Some aggressive lymphomas are highly sensitive to treatment.
Main Treatment Options for Non-Hodgkin Lymphoma
Depending on the subtype and clinical situation, treatment may involve one or more of the following:
- Active surveillance
- Chemotherapy
- Monoclonal antibody therapy
- Targeted therapy
- Immunotherapy
- Bispecific antibodies
- Radiation therapy
- CAR T-cell therapy
- Stem cell transplantation
- Selected surgery or infection-directed treatment for particular lymphoma types
1. Active Surveillance: When Treatment Does Not Need to Start Immediately
One of the most surprising non-Hodgkin lymphoma treatment options is sometimes no immediate anti-cancer treatment. This approach is known as:
- Active surveillance
- Watch and wait
- Watchful waiting
It may be appropriate for selected patients with slow-growing lymphomas such as follicular lymphoma when the disease:
- Is not producing significant symptoms
- Has a relatively low tumour burden
- Is not threatening organ function
- Is not progressing rapidly
*AI-generated image - for illustration only. Clinical accuracy is not guaranteed.
2. Chemotherapy
Chemotherapy remains an important treatment for many forms of NHL. Because chemotherapy circulates throughout the bloodstream, it can reach lymphoma cells in multiple lymph nodes and organs. This makes it particularly useful for widespread disease.
R-CHOP
One of the best-known regimens is R-CHOP, which combines:
- Rituximab
- Cyclophosphamide
- Doxorubicin
- Vincristine
- Prednisone
It remains an important treatment for diffuse large B-cell lymphoma (DLBCL) and selected other B-cell lymphomas.
3. Targeted Therapy
Targeted therapies interfere with biological pathways or proteins that lymphoma cells depend on. Unlike conventional chemotherapy, these medicines are designed around particular features of the cancer. Examples include:
- BTK inhibitors such as acalabrutinib, zanubrutinib, and pirtobrutinib in appropriate lymphoma settings
- BCL-2 inhibitors such as venetoclax in selected diseases
- Antibody-drug conjugates such as polatuzumab vedotin
- Other molecularly targeted drugs for specific NHL subtypes
4. Immunotherapy
Immunotherapy helps the immune system identify or attack lymphoma cells more effectively. Antibody therapy itself is a form of immune-based treatment, but several newer approaches are now available.
Bispecific Antibodies
Bispecific antibodies are designed to attach to two different targets at once. For B-cell lymphoma, one part commonly attaches to a protein on the lymphoma cell while another connects with a T cell.
This brings the patient's immune cell close to the lymphoma cell so it can attack it. Bispecific antibodies have become important options for selected patients with relapsed or refractory B-cell lymphomas, including some cases of follicular lymphoma and DLBCL. They are not automatically used as first treatment for every patient.
5. Radiation Therapy
Radiation therapy uses high-energy radiation to treat lymphoma in a defined area. It can be particularly useful for:
- Selected stage I or stage II indolent lymphomas
- Localised lymphoma
- Bulky masses in particular situations
- Areas producing significant pain or pressure symptoms
6. CAR T-Cell Therapy
CAR T-cell therapy is an advanced form of personalised immunotherapy. During treatment:
- T cells are collected from the patient's blood.
- The cells are genetically modified in a laboratory.
- The modified cells are trained to recognise a protein on lymphoma cells.
- The CAR T cells are returned to the patient.
- The engineered cells then seek and attack lymphoma cells.
*AI-generated image - for illustration only. Clinical accuracy is not guaranteed.
CAR T-cell therapy has become an important option for selected patients with B-cell lymphomas such as:
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Mantle cell lymphoma
- Other selected aggressive B-cell lymphomas
7. Stem Cell Transplantation
Stem cell transplantation may be used for selected patients whose NHL has returned or is at high risk of returning.
Autologous Stem Cell Transplant
An autologous transplant uses the patient's own blood-forming stem cells. The cells are collected and stored before high-dose treatment. They are then returned to the patient to restore bone-marrow function. This approach remains important for selected chemotherapy-responsive relapsed lymphomas.
Allogeneic Stem Cell Transplant
An allogeneic transplant uses stem cells from a donor. It can produce an additional immune effect against lymphoma, but it also carries greater risks, including graft-versus-host disease. It is therefore reserved for carefully selected circumstances.
Treatment Options for Diffuse Large B-Cell Lymphoma
DLBCL is an aggressive lymphoma but is often treated with the goal of cure. First-line treatment may include:
- R-CHOP
- Pola-R-CHP for appropriate patients
- Other subtype- or patient-specific regimens
Radiation may be added in selected localised or bulky cases.
If DLBCL returns or does not respond sufficiently, options may include:
- Different systemic therapy
- Autologous stem cell transplant in selected treatment-responsive patients
- CAR T-cell therapy
- Bispecific antibodies
- Other antibody or targeted therapies
Treatment Options for Follicular Lymphoma
Follicular lymphoma is usually slower-growing than DLBCL. If it is not causing problems, active surveillance may be appropriate. When treatment is needed, possibilities include:
- Radiation for selected localised disease
- Rituximab
- Obinutuzumab
- Anti-CD20 antibody plus chemotherapy
- Lenalidomide combined with rituximab in selected patients
- Targeted or antibody-based treatment after relapse
- Bispecific antibody therapy in selected relapsed disease
- CAR T-cell therapy for eligible patients after previous treatments
Treatment Options for Mantle Cell Lymphoma
Mantle cell lymphoma has a treatment pathway distinct from both follicular lymphoma and DLBCL. Depending on age, symptoms, disease biology, and medical fitness, treatment may include:
- Rituximab-containing systemic therapy
- Chemotherapy
- BTK inhibitors
- Maintenance treatment in selected patients
- Stem cell transplantation
- CAR T-cell therapy for selected relapsed disease
Some patients with slowly progressing, asymptomatic mantle cell lymphoma may initially undergo observation rather than immediate treatment.
Treatment Options for MALT Lymphoma
Mucosa-associated lymphoid tissue (MALT) lymphoma shows why knowing the exact NHL subtype matters. Some gastric MALT lymphomas are associated with Helicobacter pylori infection.
In appropriate early-stage H. pylori-positive gastric MALT lymphoma, treatment may begin with antibiotics aimed at eradicating the infection. The lymphoma can regress when the underlying infection is successfully treated.
If the lymphoma persists or is unrelated to H. pylori, options may include radiation therapy, rituximab, or systemic treatment depending on disease extent. Antibiotics are not a general treatment for other forms of NHL.
Treatment Options for T-Cell Non-Hodgkin Lymphoma
T-cell lymphomas account for a smaller proportion of NHL and include several distinct diseases. Some peripheral T-cell lymphomas are treated initially with doxorubicin-containing chemotherapy such as:
- CHOP
- CHOEP
If the lymphoma expresses CD30, treatment with brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone may be appropriate for certain subtypes, particularly systemic anaplastic large cell lymphoma. Stem cell transplantation may be considered for selected patients. Because T-cell lymphomas are less common and biologically diverse, obtaining an accurate pathology diagnosis is particularly important.
What Does Relapsed or Refractory Non-Hodgkin Lymphoma Mean?
Relapsed lymphoma means the disease returned after responding to treatment. Refractory lymphoma means it did not respond adequately or progressed during or soon after treatment. Modern treatment options for relapsed or refractory NHL have expanded considerably.
Depending on subtype, previous therapy, and overall health, options may include:
- A different chemotherapy or chemoimmunotherapy regimen
- Targeted medicines
- Monoclonal antibodies
- Bispecific antibodies
- CAR T-cell therapy
- Autologous or allogeneic stem cell transplantation
How Do Doctors Decide Between the Options?
A useful way to understand NHL treatment selection is:
| Clinical Situation | Possible Treatment Direction |
|---|---|
| Asymptomatic indolent lymphoma | Active surveillance may be appropriate |
| Localised indolent lymphoma | Radiation may sometimes provide long-term disease control |
| Aggressive B-cell lymphoma | Prompt chemoimmunotherapy is commonly required |
| CD20-positive B-cell lymphoma | An anti-CD20 antibody may form part of treatment |
| Relapsed B-cell lymphoma | Targeted therapy, bispecific antibodies, CAR T-cell therapy, transplant, or other systemic therapy may be considered |
| Selected CD30-positive T-cell lymphoma | Brentuximab vedotin-containing treatment may be appropriate |
The Bottom Line
Non-Hodgkin lymphoma treatment options range from careful observation to chemotherapy, antibody therapy, targeted medicines, radiation, bispecific antibodies, CAR T-cell therapy, and stem cell transplantation. But these treatments are not interchangeable.
An asymptomatic patient with slow-growing follicular lymphoma may need only active surveillance initially, while someone with DLBCL usually needs prompt systemic treatment with curative intent. A patient with mantle cell lymphoma may benefit from a BTK inhibitor at some point in treatment, while a person with CD30-positive T-cell lymphoma may require an entirely different approach.
Relapsed disease also has its own treatment pathway, with newer immune and cellular therapies providing options that were not available in earlier eras of lymphoma care.
*AI-generated image - for illustration only. Clinical accuracy is not guaranteed.
The most useful question therefore is not: “Which non-Hodgkin lymphoma treatment is strongest?” It is: “What exact NHL subtype do I have, how is it behaving, and which treatment has the strongest evidence for this particular stage of my disease?”
